
Coiled Therapeutics is a clinical-stage precision oncology company whose lead asset AO-252 is a brain-penetrant small molecule targeting TACC3.
coiledplc.comCrawled Nov 17, 2026
Coiled Therapeutics is a clinical-stage precision oncology company advancing first-in-class TACC3 inhibitors. Listed on London Stock Exchange AIM market.
Coiled Therapeutics begins patient enrollment in two dose cohorts for its reformulated experimental cancer drug. The company tests the updated version of its therapy, aiming to evaluate safety and efficacy in clinical trials. This marks progress in advancing its pipeline toward potential treatment options for cancer patients.
Coiled Therapeutics appoints Professor Ozgur Sahin as a Scientific Advisor to advance its lead cancer therapy, AO-252. The company develops targeted treatments, leveraging Sahin’s expertise in oncology research. AO-252 is in development as a potential precision medicine for cancer patients.
Coiled Therapeutics reports an 80% clinical benefit rate (CBR) in its Phase I/II trial of **AO-252**, a first-in-class TACC3 inhibitor, for patients with advanced solid tumors. The drug targets TACC3, a protein linked to tumor growth. Early results suggest potential efficacy in treating refractory cancers. The trial continues to assess safety and efficacy in this patient population.
Coiled Therapeutics achieves an 80% clinical benefit rate in trials using its experimental oncology drug AO-252 when administered twice daily. The improved efficacy follows adjustments to the dosing regimen in the latest patient cohort. The company develops clinical-stage cancer treatments targeting unmet medical needs.
Coiled Therapeutics plc, a clinical-stage oncology company, has joined the AIM market for trading. The company focuses on developing therapies for cancer patients. This marks its official admission to trading on the AIM exchange, allowing investors to engage in its first day of dealings.